
## Hendrik Neubert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6451745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays. Clinical Chemistry, 2016, 62, 48-69.	3.2	187
2	Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human Î <sup>2</sup> -Nerve Growth Factor. Analytical Chemistry, 2013, 85, 1719-1726.	6.5	117
3	Label-Free Detection of Differential Protein Expression by LC/MALDI Mass Spectrometry. Journal of Proteome Research, 2008, 7, 2270-2279.	3.7	100
4	Highly Specific and Sensitive Measurements of Human and Monkey Interleukin 21 Using Sequential Protein and Tryptic Peptide Immunoaffinity LC-MS/MS. Analytical Chemistry, 2013, 85, 5522-5529.	6.5	96
5	Online High-Flow Peptide Immunoaffinity Enrichment and Nanoflow LC-MS/MS: Assay Development for Total Salivary Pepsin/Pepsinogen. Clinical Chemistry, 2010, 56, 1413-1423.	3.2	92
6	Clinical Pharmacokinetic Assessment of an Anti-MAdCAM Monoclonal Antibody Therapeutic by LC-MS/MS. Analytical Chemistry, 2012, 84, 5959-5967.	6.5	81
7	Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs, 2016, 8, 1064-1078.	5.2	72
8	Mass Cytometry: A Highly Multiplexed Single-Cell Technology for Advancing Drug Development. Drug Metabolism and Disposition, 2015, 43, 227-233.	3.3	71
9	Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision. Clinical Chemistry, 2020, 66, 282-301.	3.2	69
10	An immunoaffinity liquid chromatography–tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Analytical Biochemistry, 2010, 399, 202-210.	2.4	68
11	Assessing Immunogenicity in the Presence of Excess Protein Therapeutic Using Immunoprecipitation and Quantitative Mass Spectrometry. Analytical Chemistry, 2008, 80, 6907-6914.	6.5	59
12	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 –) Tj ETQ	ე0.0.0 rgB 1.5	T /Overlock 1 47
13	Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD. Bioanalysis, 2012, 4, 2589-2604.	1.5	34
14	A Physiologicallyâ€Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From <i>In Vitro</i> Data. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 738-747.	2.5	34

15	Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS. Analytical Chemistry, 2016, 88, 4239-4247.	6.5	33	
----	--	-----	----	--

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) Tj ETQq0 0 0 rgBT /Overlock 10 1.5 32

17	Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities. Scientific Reports, 2018, 8, 7781.	3.3	30
18	Human FcRn Tissue Expression Profile and Half-Life in PBMCs. Biomolecules, 2019, 9, 373.	4.0	27

#	Article	IF	CITATIONS
19	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq1	1 0178431	l4 r <b>g8</b> T /Overl
20	2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome ( <u>Part 1</u> – Recommendations) Tj E	TQq0 0 0 1.5	rgBT /Overloc 24
	Bioanalysis, 2021, 13, 203-238.		
21	Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease. PLoS ONE, 2016, 11, e0155368.	2.5	24
22	Quantification of biotherapeutic targets: new opportunities with immunoaffinity LC–MS/MS. Bioanalysis, 2014, 6, 1731-1733.	1.5	23
23	Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs, 2016, 8, 848-853.	5.2	23
24	Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 77-86.	1.3	23
25	Large-scale implementation of sequential protein and peptide immunoaffinity enrichment LC/nanoLC–MS/MS for human β-nerve growth factor. Bioanalysis, 2016, 8, 753-764.	1.5	21
26	Clinical chemoproteomicsâ $\in$ "Opportunities and obstacles. Science Translational Medicine, 2017, 9, .	12.4	21
27	Quantification of protein biomarkers in tissues: new capabilities with pellet digestion peptide immunoaffinity LC–MS/MS. Bioanalysis, 2016, 8, 1551-1555.	1.5	18
28	Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS. Proteomics - Clinical Applications, 2016, 10, 597-604.	1.6	17
29	Protein Turnover Measurements in Human Serum by Serial Immunoaffinity LC-MS/MS. Clinical Chemistry, 2018, 64, 279-288.	3.2	15
30	Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations. Bioanalysis, 2019, 11, 2011-2024.	1.5	15
31	Online capillary weak cation exchange enrichment hyphenated to nanospray mass spectrometry for quantitation of a basic pegvisomant derived peptide. Journal of Chromatography A, 2009, 1216, 6151-6154.	3.7	11
32	Measuring the Turnover Rate of Clinically Important Plasma Proteins using an Automated SISCAPA Workflow. Clinical Chemistry, 2019, 65, 492-494.	3.2	11
33	Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. Gene Therapy, 2022, 29, 608-615.	4.5	11
34	Serum β-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys. NeuroReport, 2014, 25, 829-832.	1.2	5
35	Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease. MAbs, 2018, 10, 62-70.	5.2	4
36	A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs. Frontiers in Bioinformatics, 2021, 1, .	2.1	4

#	Article	IF	CITATIONS
37	Quantification of Protein Biomarkers Using Liquid Chromatography Tandem Mass Spectrometry. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 87-98.	0.6	Ο
38	Application of Immunoaffinity Mass Spectrometry (IA-MS) for Protein Biomarker Quantification. Methods in Molecular Biology, 2022, 2466, 111-119.	0.9	0